Biotech Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
AstraZeneca
Second study of Seroquel for depressive episodes from bipolar I and II confirms first study
June 23rd, 2006
AstraZeneca (AZN) announced results presented at the annual meeting of the American Psychiatric Association (APA) from a large-scale study called BOLDER II, which examined Seroquel (quetiapine fumarate) as a monotherapy treatment for depressive episodes in patients with bipolar I and II disorders. Results from this clinical trial showed significant improvement in measures of depressive symptoms in patients taking Seroquel, confirming the results of the BOLDER I study (Am J Psychiatry 2005;162:1351-1360)(Annual Meeting of the American Psychiatric Association, 2006, Toronto, Canada, research poster board NR600). An additional analysis of the BOLDER...
Source: Biotech Law Weekly (2006-06-23)
|
